key: cord-0709984-sz8twft6
authors: Divisi, Duilio; Zaccagna, Gino; Angeletti, Chiara; Cicerone, Elena; De Vico, Andrea; Moretti, Riccardo; Imbriglio, Giovanna; Carbuglia, Nadia; Quaglione, Gina Rosaria; Chiatamone Ranieri, Sofia; Crisci, Roberto
title: Pleural empyema associated with alveolar‐pleural fistulas in severe acute respiratory syndrome coronavirus 2
date: 2021-06-22
journal: Clin Case Rep
DOI: 10.1002/ccr3.4262
sha: f04c5ac14119ec945c471329b4163ea21cd8a9d0
doc_id: 709984
cord_uid: sz8twft6

Surgery in COVID‐19 disease complicated by APF represents the last life‐saving treatment option. The choice of the therapeutic period to indicate this approach is fundamental. In fact, the clinical stability of patient is necessary in order to allow single‐lung ventilation and to minimize postoperative sequelae.

We describe a SARS-CoV-2 characterized by pneumonia, alveolar-pleural fistulas, and empyema. Patient, initially treated with noninvasive ventilation, required an orotracheal intubation due to the worsening of the clinical conditions. Despite medical treatment with empiric antibiotics, hydroxychloroquine, low molecular weight heparin, glucocorticoids, and monoclonal antibody, patient displayed a right pneumothorax on the thirteenth day, needing pleural drainage. The persistent air leaks and empyema, in spite of targeted antibiotics, required surgical approach, with empyemectomy and suture of fistulas. In this case report, we evaluate the alternation, also chronologically, of the different therapeutic moments. This management allowed the survival of patient, in spontaneous breathing with tracheotomy, although the wide destruction of the lung parenchyma architecture.

Coronavirus disease completely subverts the lung structure through parenchymal necrosis due to widespread vascular thrombosis, 1 a wide inflammatory reaction and a squamous metaplasia linked to trauma on the mucous membrane of the bronchioles. The diffusion and adaptability of the coronavirus to the human population seem to be linked to the action of furin, 2,3 which cleaves the S protein into two subunits: S1 responsible for recognizing the angiotensinconverting enzyme-2 (ACE2) receptor and S2 responsible for the passage of the virus inside cells. In such a clinicalpathological situation, the development of empyema sustained by alveolar-pleural fistulas reduces the chance of treatment and survival of patients.

A fifty-two-year-old man, showing fever and dyspnea for 4 days, underwent nasopharyngeal swab, which allowed diagnosis of the novel coronavirus disease 2019 (COVID-19). The worsening of breathing initially required hospitalization and noninvasive ventilation; subsequently, the patient's clinical conditions necessitated an orotracheal intubation associated with invasive mechanical ventilation (tidal volumes = 6 mL/Kg predicted body weight), positive endexpiratory pressure (PEEP ≤12 cm H 2 O), and drive pressure ≤12 cm H 2 O. Medical treatment consisted of oral hydroxychloroquine 200 mg twice a day, intravenous (iv) piperacillin/tazobactam 4.5 g three times a day, subcutaneous enoxaparin 6000 UI once a day, iv dexamethasone 20 mg once a day, iv noradrenaline 0.1 mcg/Kg/min, and iv tocilizumab 8 mg/Kg on 3rd day of hospitalization and 12 hours following the first administration. Furthermore, patient was treated with neuromuscular agents (rocuronium) and pronosupination position for 12 hours a day. A right pneumothorax (Pnx), needing chest drainage 28 French (Fr) linked to digital system, was displayed on 13th day ( Figure 1 ). The air leaks associated with the inability to properly ventilate the patient required the placement of endobronchial obturator into the intermediate bronchus. Percutaneous tracheotomy was carried out on 15th day. Chest X-ray at 17th day displayed a right pleural effusion ( Figure 2 ); pleural fluid culture revealed a pseudomonas aeruginosa. Such infection was treated with targeted antibiotics (meropenem three times a day and gentamicin 240 mg per day). RT-PCR was tested negative for SARS-CoV-2 in the bronchoalveolarlavage fluid at 19th day and 21st day, which also confirmed the pseudomonas aeruginosa infection related to empyema (Figures 3 and 4) . Empyemectomy was carried out at 31st day, after stabilization of hemodynamic and respiratory parameters, by muscle-sparing axillary minithoracotomy (MSAM). Three alveolar-pleural fistulas (2 in the lower lobe and 1 in the middle lobe) were sutured by black silk separate stitches two zeros and two 32 French pleural drainages were placed. Endobronchial blocker was left in place to protect the sutures, and it was removed on the 4th postoperative day while pleural drainages were withdrawn on the 7th. On the 20th day, patient was discharged and transferred to rehabilitation hospital in spontaneous breathing (O 2 , 2 l/min with tracheotomy) and normocapnia, with respiratory rate 18/minute and PO 2 /FiO 2 > 350. The clinical history was summarized in Table 1 and in Table 2 

Our experience allows different key points to discuss. Pneumothorax (pnx) was due to thrombosis of interstitial blood vessels, followed by parenchymal necrosis and loss of tissue elasticity. Singhania Obviously, the thoracostomy tube placement must be carried out by an experienced doctor or surgeon, assisted only by a staff member as recommended by the AAST. 9 We used F I G U R E 3 Apical and basal right pneumothorax (yellow arrows) with collapse and atelectasis of the pulmonary parenchyma. Pleural drainage is clearly visible (blue ring). Some air cavitations (orange arrows) are recognized in the lower lobe. These show serpiginous morphology as bronchiectasis and lobulated morphology as pneumatocele. Furthermore, there is a pleural effusion (red arrows) with hyperdense and irregular aspects as corpuscular component

Bilaterally, diffused ground-glass (green arrows) and interstitial lung disease with an increase in the thickness of the septa are recognized, associated with a basal parenchymal consolidation of the left lower lobe. Moreover, paraseptal emphysema changes are also recognized the closed digital chest drain system as it reduces the aerosolization of virus and the exposure of the team, although an alternative method (HEPA filter) has been proposed by Carvalho et al 10 Concerning the treatment of APF, as it was a Grade C air leak according to Cerfolio classification 11 associated with empyema, we opted for a temporary endobronchial blocker in order to stabilize ventilation followed by surgical intervention. In fact, the pleural cavity cleaning and decortication to avoid persistence of infection as well as the suture in layers with separate stitches of APFs are mandatory. The use of staplers appears not to be indicated on a fibrotic, necrotic, and infected parenchyma, as it could not ensure the perfect seal but determine further lacerations of the lung. The last aspect to be evaluated concerns the histological alteration of the pulmonary parenchyma, which creates doubts about the restoration of tissue integrity. Histologically, the SARS-CoV-2 infection associated with an acute respiratory distress syndrome (ARDS) is characterized by the vascular and respiratory epithelium damages. The angiotensin-converting enzyme-2 (ACE2) receptors, T A B L E 2 Laboratory, blood gas analysis, and cardiac parameters during ICU stay also widely expressed in the endothelial cells, allow the virus to determine a widespread endotheliitis, 1,4 with hyperplasia and subsequent thrombosis. Ackermann et al 12 described the same lesions affecting lungs, kidneys, heart, and liver in the autopsy of patients who died from COVID-19. In addition, the binding of coronavirus to ACE2 receptors and the angiotensin II can directly damage pneumocytes by activation of immune cells system, 13 reducing the production of surfactant and lung elasticity with development of fibrosis. The cytokine storm was highlighted in our experience by the dosage of Interleukin six between 523.9 pg/mL and 3618 pg/mL in our experience. This may explain the pulmonary edema, interstitial inflammatory infiltrates with lymphocytes predominance, hyaline membrane formation (indicating an ARDS) but it is also related to squamous metaplasia that has already been noticed in deceased patients 14 and we have found in our live patient. These histopathologic findings occur through two distinctive manifestations 15 : an exudative early phase and a proliferative and fibrotic phase. The bronchial response to stress or irritation due to APF, as we have observed, was formed on disruption of airway architecture, making the regression of squamous metaplasia extremely difficult. This aspect was also confirmed by immunohistochemistry which accounts for the alveolar damage spread in COVID-19 infection. In conclusion, it is evident that the attack on the vessels and the airway are the two key moments of the SARS-CoV-2 infection with ARDS, causing an impairment of both perfusion and ventilation. In fact, the lesions found in the lungs consisted of the destruction of the pulmonary parenchyma. Surgery becomes necessary in case of fistulas, whether or not associated with infection of the pleural cavity. The indication for surgical approach at the time of greater clinical stability facilitated the functional recovery of patient.

Piperacillin-Tazobactam/15. Meropenem +Gentamicin/18 LLL PNX/Chest tubes APFs/Bronchial blocker Empyema/ Thoracotomy-Empyemectomy, APFs Sutures 51d/Hospital discharge F I G U R E 5 A, Arteriole occluded with micro-channeling aspect (white arrow), intimal hyperplasia, and siderophages (blue arrows). Chronic peribronchiolar inflammation (green arrows) coexists; B, Thrombosed arterioles (red arrow) associated with an intense inflammatory reaction (green arrows) and micro-channeling aspects (white arrows); C, Subpleural pulmonary parenchyma with intense inflammation (green arrow). The bronchiole shows fistula (black arrows) and extensive squamous metaplasia (orange arrows). On the side, a thrombosed artery (red arrow) due to intimal hyperplasia with vascular micro-recanalization (white arrow) is observed; D, Alveolar-pleural fistula (black arrows), with squamous metaplasia (orange arrows) of bronchial epithelium

Involvement of spike protein, Furin, and ACE2 in SARS-CoV-2-related cardiovascular complications

Furin cleavage sites naturally occur in coronaviruses

The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin

Current overview on hypercoagulability in COVID-19

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuha, China: a single-centered, retrospective, observational study

Early histologic findings of pulmonary SARS-CoV-2 infection detected in a surgical specimen

Inside the lungs of COVID-19 disease

Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia

Tube thoracostomy during the COVID-19 pandemic : guidance and recommendations from the AAST acute care surgery and critical care committees

Safety model for chest drainage in pandemic by COVID-19

Recent advances in the treatment of air leaks

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a twocentre descriptive study

Pleural empyema associated with alveolar-pleural fistulas in severe acute respiratory syndrome coronavirus 2

The authors have no acknowledgements to declare.

The authors have no conflicts of interest to declare.

(I) Divisi D: involved in conception, and provision of study materials or patients; (II) None: involved in administrative support; (III) Divisi D, Angeletti C, and Cicerone E: collected and assembled the data; (IV) Divisi D, Zaccagna G, and De Vico A: involved in data analysis and interpretation; (V) All authors wrote and finally approved the manuscript.

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

https://orcid.org/0000-0002-8137-7533 Andrea De Vico https://orcid.org/0000-0002-3369-5676